ArticleCA: a cancer journal for clinicians
Cancer statistics for Hispanic/Latino people, 2026.
Article in CA: a cancer journal for clinicians. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Cancer Statistics 2026-A Shout-out and Challenge to the Source!Annals of surgical oncology · 2026Article
- Routine CT reporting of vascular involvement in pancreatic ductal adenocarcinoma: completeness and association with margin-positive resection.Abdominal radiology (New York) · 2026Article
- Cancer in Hispanic communities: Lower rates, larger gaps, and the work ahead.CA: a cancer journal for cliniciansArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Hispanic/Latino population is the second largest racial and ethnic group in the United States, accounting for 20% of the total population (68 million), plus approximately 3 million Hispanic Americans residing in Puerto Rico. Herein, the American Cancer Society reports cancer occurrence, risk factors, and screening for US Hispanic people using federally funded, high-quality, population-based cancer registry data and national vital statistics and survey data. In 2026, an estimated 229,900 Hispanic people will be diagnosed with cancer, and 54,200 will die from the disease in the continental United States and Hawaii. Cancer incidence during 1998-2022 rose in Hispanic women (from 345 to 385 per 100,000) and fell in Hispanic men (from 471 to 389 per 100,000), narrowing the male-to-female incidence rate ratio from a peak of 1.40 (95% CI, 1.38-1.42) in 2002 to 1.01 (95% CI, 1.00-1.02; p = .02) in 2022. This pattern is partly driven by declining incidence of lung and prostate cancers among men and increasing incidence of breast and uterine corpus cancers among women. Although temporal trends mirror the general population, the Hispanic cancer distribution is distinct, consistent with relatively lower prevalence of smoking, alcohol drinking, and screening and higher prevalence of obesity and cancer-causing infections. Compared with White people, Hispanic people have one half the incidence of lung and urinary bladder cancers and 24% lower breast cancer but double the rate of liver, stomach, and gallbladder cancers, 61%-65% higher acute lymphocytic leukemia, and 36% higher cervical cancer. The cancer burden in Puerto Rico is distinct, with lower rates of lung cancer but higher rates of cervical, prostate, and colorectal cancers compared with other US Hispanic populations. Residents in Puerto Rico also experience lasting health care system challenges from extreme weather events. Thus, prevention efforts should target the unique cancer profile of the Hispanic population, including infection prevention and control, healthy eating, physical activity, and routine screening, especially for cervical and colorectal cancer that are 11 percentage points lower than White people.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.